- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Coverage Decisions for Personalized Medicine
Although he does not make coverage decisions, David C. Collymore, MD, MBA, believes that in the field of oncology, the science has reached a point where it has recognized certain treatments are better suited for some individuals with a specific genetic predisposition. “Cancer research is almost the standard of care for that to be the mindset for oncologists,” Dr. Collymore explained.
He believes that the progress in the field of oncology should trickle over to other disease areas. “We do see some of that in HIV treatment, like testing for resistance to certain medications. So there’s a tailored approach in other aspects of healthcare too. The next step would be for this to trickle down to more prevalent (chronic) conditions such as diabetes and hypertension that have affected our nation,” said Dr. Collymore.
Diagnostic Oversights Limit Luspatercept Benefits in MDS
May 8th 2024Investigators of a retrospective study encourage colleagues to utilize molecular testing for patients with an established diagnosis of lower-risk myelodysplastic syndromes (MDS), to be sure they don’t miss out on treatments, like luspatercept, for which they qualify.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Coexistence of HIV, Hemophilia May Lead to Increased Presence of Coronary Artery Stenosis
May 8th 2024In patients living with HIV, the cardiovascular risk factors that come with infection may lead to an increased prevalence of coronary artery stenosis, especially in those who also have hemophilia.
Read More
